Olema Oncology Showcases Innovations at J.P. Morgan Healthcare Expo
Olema Oncology to Present at Major Healthcare Event
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a dynamic clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and related conditions, is all set to present its innovative findings at the renowned J.P. Morgan Healthcare Conference. This key event takes place in San Francisco, providing an excellent platform for healthcare and investment leaders.
Presentation Highlights
Sean P. Bohen, M.D., who serves as the President and Chief Executive Officer of Olema, will lead the presentation. Scheduled for January 14, this presentation captures the attention of investors and healthcare professionals eager to learn more about Olema's pioneering work in oncology.
Live Webcast Availability
For those unable to attend in person, a live webcast of the presentation will be accessible. Attendees can find additional resources and materials under the Events and Presentations section of Olema's Investor Relations webpage.
Overview of Olema Oncology
Olema Oncology is committed to innovating the standard of care for patients diagnosed with breast cancer. The company focuses on understanding endocrine-driven cancers and how they respond to various therapies. Their lead candidate, palazestrant (OP-1250), operates as a complete estrogen receptor antagonist and is currently featured in the Phase 3 clinical trial named OPERA-01.
Pipeline Expansion
In addition to palazestrant, Olema is also advancing a potent KAT6 inhibitor (OP-3136), which holds significant promise in future therapies. This diverse product pipeline aims to combat challenges that arise from acquired resistance in hormone-driven cancers.
Headquarters and Operations
Headquartered in San Francisco, Olema further extends its reach with a significant operational presence in Cambridge, Massachusetts. This strategic location aids in collaboration and innovation within the biopharmaceutical sector.
Contact Information
For media inquiries or further information, please reach out to:
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
Email: media@olema.com
Frequently Asked Questions
What is the significance of the J.P. Morgan Healthcare Conference?
The J.P. Morgan Healthcare Conference is a pivotal event where leaders from the healthcare and investment sectors converge to discuss new innovations and strategies in the industry.
Who will be presenting for Olema Oncology?
Sean P. Bohen, M.D., President and CEO of Olema, will be delivering the presentation.
What is palazestrant?
Palazestrant (OP-1250) is Olema Oncology's leading product candidate, which acts as a comprehensive estrogen receptor antagonist and is essential in their current clinical trials.
Where can I access the presentation materials?
The presentation materials will be accessible through the Investor Relations section of Olema's website.
How can I contact Olema for more information?
For inquiries, you can contact Courtney O’Konek, Vice President of Corporate Communications, via email at media@olema.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.